Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
checkpoint inhibitors
Biotech
Boehringer axes MASH deal after OSE asset fails to show efficacy
The French biotech is downsizing its pipeline after its Boehringer-partnered SIRPĪ± antagonist failed to show efficacy in a phase 2 MASH study.
Gabrielle Masson
Mar 2, 2026 2:16pm
Sensei shrinks workforce by 65% as layoff warning comes to pass
Nov 14, 2025 10:33am
Sensei drops sole clinical-stage cancer drug, plans layoffs
Oct 30, 2025 9:52am
GSK loses hope for CD226 cancer therapies, dropping ph. 2 assets
Oct 29, 2025 6:29am
Scancell picks winner from phase 2 cancer vaccine face-off
Jul 22, 2025 9:38am
Hummingbird uses VISTA buzz to secure $290M pact for tumor drug
Jun 26, 2025 4:53am
